This ZOM stock forecast article was written by Viktoriya Voronchuk – Financial Analyst intern 
Read The FullPremium Article
– Barry D. Quart, Pharm.D., CEO of Heron Therapeutics.
(Source: smarteranalyst.com)
Just in three months from March 25th, 2018, Heron Therapeutics Inc (NYSE: HRTX) has gained 46.99%. The main reason for such an incredible movement is the news released on June 25th that HTX-011 has received the Breakthrough Therapy designation from the FDA. HTX-011 is an investigational, and long-acting formulation for Postoperative Pain Management, developed by HRTX.
The formulation achieved the designation thanks to the Phase 2 and some of Phase 3 studies. The Breakthrough Therapy designation allows Heron Therapeutics to expedite the development of the drugs. The success of HTX-011 will significantly reduce the postoperative pain intensity as well as the addiction of opioids. Opioids are a class of drugs that are used as medicines to relieve pain and relax the body. According to Heron Therapeutics, there are more than 40 million patients who undergoing surgical procedures are prescribed to this class of drugs. Out of 40 million, 2.6 become persistent users, while 440,000 become addicted. Hence, if success, HTX-011 will become a huge solution for postoperative pain management.
(Source: Centers for Disease Control and Prevention)
On May 25, 2017, I Know First has issued a bullish 3-month prediction for HRTX with the signal of 28.44 and the predictability of 0.53. 3 months after the bullish signal, HRTX shot up to $41.45 (46.99% upside), in line with our forecast.
Current I Know First subscribers received this bullish XOMA forecast on March 25, 2018.
To subscribe today click here.
How to interpret this diagram
Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.
Heron Therapeutics, Inc., (NASDAQ: HRTX) incorporated on February 5, 1987, is a biotechnology company. The Company is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection. The Company’s product candidate, SUSTOL (granisetron) injection, extended release, is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). SUSTOL is in Phase III clinical trials. The New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) for SUSTOL. The Company has initiated a placebo-controlled, dose-finding, Phase II clinical trial for HTX-011 in approximately 100 patients undergoing abdominoplasty. HTX-011 is also being evaluated in a placebo-controlled, dose-finding, Phase II clinical trial in approximately 100 patients undergoing inguinal hernia repair.
Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.
Disclaimer:
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
